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Background: There is growing interest in the use of diammine silver fluoride (DSF) as a topical agent to treat
dentin hypersensitivity and dental caries as gauged by increasing published research from many parts of the world.
While DSF has been available in various formulations for many years, most of its pharmacokinetic aspects within the
therapeutic concentration range have never been fully characterized.
Methods: This preliminary study determined the applied doses (3 teeth treated), maximum serum concentrations,
and time to maximum serum concentration for fluoride and silver in 6 adults over 4 h. Fluoride was determined
using the indirect diffusion method with a fluoride selective electrode, and silver was determined using inductively
coupled plasma-mass spectrometry. The mean amount of DSF solution applied to the 3 teeth was 7.57 mg (6.04 μL).
Results: Over the 4 hour observation period, the mean maximum serum concentrations were 1.86 μmol/L for fluoride
and 206 nmol/L for silver. These maximums were reached 3.0 h and 2.5 h for fluoride and silver, respectively.
Conclusions: Fluoride exposure was below the U.S. Environmental Protection Agency (EPA) oral reference dose. Silver
exposure exceeded the EPA oral reference dose for cumulative daily exposure over a lifetime, but for occasional use
was well below concentrations associated with toxicity. This preliminary study suggests that serum concentrations of
fluoride and silver after topical application of DSF should pose little toxicity risk when used in adults.
Clinical trials registration: NCT01664871.
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We previously demonstrated that diammine silver fluoride
(DSF) applied topically to teeth of adults reduced the pain
response to a cold air blast [1]. The pain reduction
increased from 24 h to 7 days [1], and was much greater
than with similar treatment with fluoride varnish [2].
Others have shown its effectiveness in root [3] and coronal
dental caries [4]. It may also be a substitute for fissure sea-
lants [5]. No adverse changes to teeth or intraoral tissues
have been reported. Earlier, Gotjamanos and Ma [6] pub-
lished an animal study suggesting that the high fluoride
concentrations in one of these products could cause
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reproduction in any medium, provided the orFree silver ions are principally responsible for the anti-
microbial action of diammine silver fluoride (DSF). It is
widely known that silver ions denature enzymes of bac-
terial organisms by binding to reactive groups, resulting
in their precipitation and inactivation [7,8]. Silver reacts
with their thiol groups to form silver sulfides. Silver also
reacts with the amino-, carboxyl-, phosphate-, and
imidazole-groups and diminishes the activities of lactate
dehydrogenase and glutathione peroxidase [9]. Bacteria
are, in general, affected by this oligodynamic effect. Fur-
ther, Knight and colleagues [10] have demonstrated that
Streptococcus mutans is unable to form a biofilm on dia-
mmine silver fluoride-treated dentinal surfaces.
In early studies of inhibition and killing properties
against oral bacteria, Thibodeau and colleagues [11]
found silver ions were effective against broadly-infected
dentin samples and several specific oral bacteria,
including S. mutans GS-5, R. dentocariosa (ATCCl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(ATCC 17745), and N. subflava. Moreover, the mini-
mum inhibitory concentrations of silver ions generated
from multiple sources (i.e., from AgF, AgNO3, or elec-
trically generated in solution) were equipotent [11] irre-
spective of the source, indicating that the antibacterial
properties were solely dependent on the concentration
of silver ions and not the specific compound or its
other components. Tanzer and colleagues [12] reported
that a single application of diammine silver fluoride
topical treatment on rats with an established flora was
associated with decrease of total recoverable facultative
flora and S. mutans counts on teeth. At 62 days post-
inoculation in this well-established animal model of
human disease, the absolute recoveries of total flora
and mutans streptococci were reduced by 34-47% (all
p <0.05) compared with groups receiving 5000 ppm F as
sodium fluoride neutral gel or distilled water. These data
are consistent with published in vitro studies [13,14].
Other than our own clinical study [1] and the animal
study by Gotjamanos and Ma [6] no investigator has for-
mally studied the safety of this widely used agent. The
aim of this preliminary study was to characterize the
short term pharmacokinetics of fluoride and silver in
serum, subsequent to oral ingestion of DSF from topical
application to teeth of adults.Methods
Participants
Six healthy volunteers (4 females, mean age 36.2, range
23–52 y) were recruited from staff members of the
Universidad Católica de Santa María, Arequipa, Peru.
Each had gingival recession exposing non-carious cemen-
tum. Participants were taking no medications and had
most permanent teeth present. Participants were asked to
avoid fish and tea for 12 h before the study and not use
fluoridated toothpaste in the preceding 4 hours. The
Comité de Etica de Investigacion, Universidad Católica de
Santa María approved the study and informed consent
was obtained. The study registration is NCT01664871.Study agent
DSF [Ag(NH3)2 F, CAS RN 33040–28–7, Saforide, Toyo
Seiyaku Kasei Co. Ltd. Osaka, Japan] was used. DSF is
clear and colorless, with a weak odor of ammonia. The
38% solution contains between 24.4-28.8% (w/v) silver
(Ag), and 5.0-5.9% fluoride (F). Concentrations of Ag
and F in the DSF used for this study were 24.9% and
5.5%, respectively, and the specific gravity was 1.253 at
25°C (Certificate of Analysis Lot #155060 from the
manufacturer). Diammine silver fluoride is also referred
to in the literature as silver diammine fluoride, silver
diamine fluoride or silver fluoride.Procedures
Three maxillary teeth (cuspid and premolars) in the
same quadrant were treated. Three teeth were treated
because this was the average number of sensitive teeth
reported in an epidemiological study of adults [15]. The
teeth were free of restorations or cavitation. The facial
(buccal) surface was dried with cotton gauze and then
DSF was applied to the cervical area of each tooth. The
teeth were isolated in order to avoid wetting the brush
with saliva. Each tooth was coated using a separate micro-
brush, which was dipped in the DSF and weighed before
and after the application using an analytical balance
(Model S2000, Kern & Sohn GmbH, Balingen, Germany).
The sum of the differences in weight of material applied
was calculated for each participant. The teeth were not
rinsed after application, however, the subjects were
allowed to swallow as necessary during the 4 hour obser-
vation period.
Blood collection
Immediately before application of DSF and then again
at approximately 30 min, 1, 2, 3 and 4 h after applica-
tion, blood was obtained from an antecubital vein. An
attempt was made to collect at least 5 mL at each time
point although the amount collected varied. The time
periods were picked based on a previous pharmacokin-
etics study of fluoride varnish [16]. The blood was
transferred to a fluoride-free plastic vacuum collection
tube with clot activator (BD Vacutainer Plus Plastic
Serum Tube, BD Diagnostics, NJ, USA). The tubes were
spun at 1100 × g for 10 min and serum transferred by
plastic pipette to 2 mL plastic cryogenic tubes. The
samples were frozen and transported to the University
of Washington for analysis.
Analysis
Fluoride
Samples were thawed and analyzed in duplicate or trip-
licate using the diffusion and detection method with
hexamethyldisiloxane (HMDS) and Orion F-sensitive
electrode [17,18]. To improve recovery of the fluoride,
the pre-diffusion step was omitted [19], and seals were
completed before mixing 1 mL of 3 mol/L H2SO4-
saturated HMDS with 1 mL of serum [20]. The trapping
solution was 10 μL of 1 M NaOH. It was dried down to
eliminate variability of evaporation and residual HMDS
before adding 100 μL 3 mol/L acetic acid to a final pH 3.4.
Standards were 10 and 100 μmol/L fluoride in the same
final concentration of NaOH and acetic acid correspond-
ing to 1 and 10 μmol/L F in the samples. ORION F and
sleeve type reference electrodes were coupled with an
Accumet Basic 0.1 mV meter (Thermo Fisher Scientific,
Milwaukee WI, USA). Fluoride concentrations were aver-
aged and are expressed as μmol/L.
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ing 3 mL of bovine plasma to 2 tubes and letting them
set overnight before combining the 2 samples and com-
paring them with plasma directly placed in diffusion
dishes. Analyses were carried out in triplicate and values
averaged. Average concentrations (μmol/L ± SD) were
0.342 ± 0.014 and 0.320 ± 0.012, respectively (P > 0.1).
The results show that less than 2% of the fluoride in the
plasma samples came from the blood collection tubes
and clot enhancer. In a separate study, recovery of fluor-
ide (mean ± SD) of 1 nmol/mL F added to commercial
bovine plasma, and analyzed using the same method,
was 101 ± 4%.Silver
Samples were thawed and analyzed one time using
Inductively Coupled Plasma-Mass Spectrometry [U.S.
Environmental Protection Agency (EPA) 6020a Rev.1
2007]. Serum (0.5 mL) was brought to 2 mL with dilute
acid (final concentration: 2% HCl, 1% HNO3; trace
metal grade, Fisher, Fairlawn, NJ, USA). Samples were
centrifuged (1290 g) for 10 min and filtered (0.45 μm,
PTFE, 13 mm [Whatman International Ltd, Kent, UK];
all polypropylene syringe) into 15 mL polypropylene
centrifuge tubes. The samples were analyzed on an
Agilent 7500CE (Santa Clara, CA, USA) inductively-
coupled mass spectrometer (ICPMS) with He as the colli-
sion cell gas and an ASX-510 autosampler (CETAC,
Omaha, NB, USA). A Micromist nebulizer (Glass Expan-
sion, Pocasset, MA, USA) was used (1.15 L/min carrier
gas; no makeup gas). Spray chamber temperature was 2°C.
RF power was 1500 W. 107Ag was quantified using Y as in-
ternal standard. Calibrants (0, 0.5, 1, 5, 10, and 50 ng/mL)
were in 2% HCl and 1% HNO3 and were prepared from
commercial ICPMS grade solution (10,000 μg/mL, Ultra
Scientific, N. Kingstown, RI, USA) by serial dilution. Con-
centration of calibrants was confirmed by a dilution of
stock from a different manufacturer (BDH Aristar, VWR,
Radnor, PA, USA). Calibration was by weighted (1/cps)
linear regression. Instrument duplicates were run on 10%
of samples; for instrument duplicates above reporting limit
(N = 3) the average coefficient of variation was 2.8%. Data
was corrected by the procedure blank. The level of detec-
tion was approximately 0.1 ng/mL. Values of silver less
than 2 ng/mL were recorded to 2 (rounded to the same
significance as the reporting limit). The amount of silver
was converted to nmol (1 nmol = 107.8682 ng) and sil-
ver concentrations were expressed as nmol/L of serum.Soft tissue assessment
The gingiva adjacent to the application of DSF and the
mucosa generally were observed at baseline and 24 h after
treatment. Erythema, bleeding, white changes, ulcerationand pigmentation were assessed using methods developed
for an earlier study [1].
Results
Participants and amount of diammine silver fluoride
applied
Table 1 gives the body weight of participants, weight/
calculated volume of DSF applied to each participant’s
3 teeth, dose of F applied, and calculation of the current
U.S. Environmental Protection Agency (EPA) oral refer-
ence dose (RfD) for daily F exposure based on the sub-
ject’s weight. The mean subject weight was 63, range
48–84 kg. Average total weight (calculated volume) of
DSF applied was 7.57 mg (6.04 μL), corresponding to a
mean application of 0.33 mg F based on the lot analysis.
Table 2 gives the dose of Ag applied and calculation of
the current EPA oral reference dose (RfD) for daily Ag
exposure for each subject, based on their weight. The
mean total amount of Ag applied to the 3 teeth was
1.50 mg.
Serum concentrations of fluoride and silver
Plots of the total concentrations of F and Ag in serum
over time are shown in Figures 1 and 2. Serum at a single
point was lost in one of the participants (Subject 6 at
t = 1 h). The collection times vary among the participants
as a result of practical considerations in collecting the
samples. The mean maximum fluoride concentration
attained during the 4 hour observation period was
1.86 μmol/L at 3.0 h after application of DSF. The mean
maximum Ag concentration was 206 nmol/L reached
after 2.5 h. Tables 1 and 2 give the individual maximum
concentrations and time points for each participant.
Safety
Subjects reported no discomfort from the topical treat-
ment. No gingival or mucosal leukoplakia, inflammation,
pigmentation or ulceration was observed in any subject
immediately after treatment or at 24 h.
Discussion
DSF is used topically to reduce dentin hypersensitivity
in adults [1] and arrest tooth decay in both adults and
children [4]. For sensitivity in adults, a single application
reduces sensitivity by at least half [1] and application 2
or 3 times per year is sufficient clinically. In applying
DSF, no deleterious changes in the gingiva were noted in
our earlier study nor were changes seen in this work.
Direct application of various silver compounds to wounds
has been associated with localized argyria [21,22]. DSF
should therefore be applied to teeth with care when used
near areas of recent surgery, injury, or soft tissue erosion.
DSF should also be used with caution in patients habit-
ually consuming large amounts of colloidal or other
Table 1 Body weight, amount of diammine silver fluoride (DSF) applied, fluoride dose, and serum fluoride






















1 48 3.8 3.03 0.17 2.88 3.0 1.46
2 54 8.2 6.54 0.36 3.24 3.2 2.88
3 84 5.8 4.63 0.25 5.04 4.0 1.02
4 82 7.6 6.07 0.33 4.92 3.0 2.77
5 54 11.9 9.50 0.52 3.24 1.0 1.56
6 56 8.1 6.46 0.36 3.36 4.0 1.45
aCalculated based on Specific Gravity of 1.253.
bCalculated based on volume of DSF solution applied times 0.055 mg/μL.
cRfD = U.S. Environmental Protection Agency oral reference dose.
dNOAEL = no observable adverse effect level.
eCalculated based on subject weight (kg) times NOAEL of 0.06 mg/(kg d).
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tertops and irreversibly damage clothing.
Maximum serum concentrations of fluoride did not
exceed concentrations adults experience when using
fluoridated toothpaste [16]. Fluoride exposure was below
the EPA RfD [24]. Thus, the study results suggest that a
single diammine silver fluoride treatment poses no toxic
risk.
Oral exposure to metallic silver and numerous soluble
silver compounds is common [25]. For instance, intraoral
silver jewelry (piercings), and medical devices such as
silver-coated intraurethral and intravascular catheters, and
dental amalgam restorations can expose an individual to
metallic silver. Silver and silver compounds (i.e. nitrates,
chlorides, oxides, and sulfides of silver) can also be found
in food and water. In its 1990 review of the toxicology of
silver, ATSDR found no human studies of acute or chronic
oral exposure to silver that resulted in death. Rat studies
suggest the no observable adverse effect level (NOAEL)
from ingested silver is greater than 181 mg/(kg day) for
acute exposure of 14 continuous days (Table 2), [1,26].
This level is more than 75 times higher than the max-
imum amount of silver applied to the subject’s teeth in
this study.Table 2 Silver dose and serum silver pharmacokinetics after a
Subject Silver applied
(mg)a




1 0.75 0.24 2.0
2 1.63 0.27 2.1
3 1.15 0.42 4.0
4 1.51 0.41 3.0
5 2.37 0.27 1.0
6 1.61 0.28 3.0
aCalculated based on volume of DSF solution applied times 0.249 mg/μL.
bRfD = U.S. Environmental Protection Agency oral reference dose.
c NOAEL = no observable adverse effect level.
dCalculated based on subject weight (kg) times NOAEL RfD of 0.005 mg/(kg d).A recent case report [27] provides details of a patient
who consumed a cumulative dose of 200 g silver and
developed argyria, but was otherwise healthy. His con-
sumption was approximately 648 mg of colloidal silver
every day for 10 months. This is a daily dose of silver that
is 275 times higher than the maximum amount applied
as DSF in this study. DSF is intended for professional ap-
plication no more than 2–3 times per year. When used as
intended, the amount of silver applied as DSF should be
well below the level to exhibit a toxic effect. While con-
sidered ‘cosmetic’ rather than toxic effect by the FDA
[28], an irreversible blue or blue-gray discoloration of the
skin or mucous membranes (argyria), or eyes (argyrosis)
may develop with chronic exposure to silver and silver
compounds. Evidence suggests silver salts (soluble silver)
have a higher tendency to produce argyria than metallic
silver [29].
After reviewing 70 cases of argyria associated with in-
gestion of silver and silver compounds [30], the EPA
established a chronic oral RfD of 5 μg/(kg day), or about
350 μg for a 70 kg person [31]. The amount of silver
contained in the dose of DSF applied intraorally in this
study exceeded the RfD for all subjects, with 1 subject
exposed to nearly 9 times the RfD. However, the RfDpplication of diammine silver fluoride topically








Figure 1 Mean (±SD) serum fluoride(μmol/L) after topical application of diammine silver fluoride to the facial (buccal) surfaces of 3
teeth in 6 adults.
Figure 2 Silver values (nmol/L) after topical application of diammine silver fluoride to the facial (buccal) surfaces of 3 teeth in 6 adults.
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ingested every day of one’s entire life and presumably not
result in the development of argyria or argyrosis. Allow-
able short-term exposure (1–10 days) of 1.142 mg of silver
per liter of drinking water was proposed by the EPA in
May 1989 [26]. Based on argyria development reported by
Gaul and Staud [30], the EPA set the lifetime lowest allow-
able effect level (LOAEL) for silver exposure at 1 g total
dose, which is well over 400 times the maximum amount
of silver applied in this study.
Most case reports of argyria indicate a pattern of
chronic ingestion of high concentrations of colloidal or
soluble silver, with total exposure in the 1– 30 g range
[32]. Evidence from a controlled study of the use of chew-
ing gum containing silver acetate as a smoking deterrent
would suggest significantly higher concentrations of silver
exposure can be tolerated daily over several months with-
out development of argyria or argyrosis. On average, 21
participants in the study by Jensen and colleagues [33]
chewed 31.9 pieces of gum per week (4.5 pieces/day) for
up to 12 weeks. Each piece of gum contained 6 mg of sil-
ver acetate (approximately 3.9 mg silver ion) and chewing
for 30 minutes was reported to release about half of the
silver from the gum (approximately 1.9 mg silver ion).
Chewing the average number of pieces each day would
have resulted in ingesting 8.6 mg silver ion per day for
each day of the 12-week study. Some subjects reported
chewing as many as 63 pieces of gum per week (9 sticks/
day average) during the first 2 weeks of the study, giving
silver exposure as high as 17.1 mg per day. Physical exami-
nations found no signs of discoloration in the oral mu-
cosa, teeth, skin, or eyes at any time up to 6 months after
the study. Of significance, skin biopsies were assessed to
be normal by hematoxylin and eosin staining, and auto-
metallographic silver development found only a few traces
of silver in the majority of skin biopsies after participation
in the study. Examination of skin biopsies pre- and post-
silver gum treatment, found that only a ‘few’ biopsies
showed increased silver grains after completion of the sil-
ver gum treatment, compared with ‘sparse’ silver grains
seen pre-treatment.
The controlled, chronic silver exposures reported by
Jensen and colleagues [33] significantly exceed the dose
and number of applications associated with the thera-
peutic use of DSF. For example, a 70 kg person chewing
the average (4.5 pieces) or highest (9 pieces) number of
gum pieces per day would exceed the RfD for silver by
nearly 25 to 50 times, respectively. The fact that argyria or
argyrosis did not develop with these higher exposures sug-
gests it is unlikely either condition will develop from one-
time or occasional use of DSF with an exposure to silver
that is 2.5 to 5 times less. Moreover, there was no staining
of teeth or irritation of the oral soft tissues reported at
these recurring exposure concentrations over 12 weeks.The pharmacokinetics of serum silver in 4 of 6 subjects
treated with DSF in this study suggested maximum
serum concentrations of silver occurred within 1–3 h
after treatment. Apparently, delayed ingestion of DSF in
the other 2 participants resulted in a delayed maximum
serum silver level until the end of the monitoring (4 h
after DSF application) in 1 participant, and no obvious
serum silver peak in the other. For future studies examin-
ing the serum pharmacokinetics of a topically-applied,
aqueous compound such as DSF, we suggest utilization
of a plain water ‘swish and swallow’ immediately after
application to facilitate dependable clearance and inges-
tion of excess product from the oral cavity. With these
caveats, the mean maximum serum silver level was
206 nmol/L, with no participant over 270 nmol/L. These
serum silver concentrations are well below those reported
to be without toxic effect in subjects chewing silver
acetate-containing gum [33]. After two weeks of gum
chewing, the mean serum silver in the Jensen study was
512 nmol/L, decreasing to 406 nmol/L at week 6, and
387 nmol/L at week 12. The serum silver level was essen-
tially maintained above 371 nmol/L for a period of at
least 10 weeks without development of argyria or argyro-
sis. These results suggest, again, that the lower serum
silver level associated with a single application of DSF at
the dose used in this study should not induce a toxic
effect.
This was a preliminary study and, as such, the number
of subjects was limited. In addition, the follow-up period
was shorter than optimal, given likely delayed clearance
and ingestion of DSF from the oral cavity. As a result we
were not able to calculate the Area Under the Curve
(AUC) for this exposure. Despite these limitations, the
data obtained are certainly useful in preliminarily asses-
sing safety and planning future studies.
Conclusion
The short term results suggest serum concentrations of
fluoride and silver after topical application of DSF
should pose little or no toxicity risk when used in adults
and provides guidance to investigators as they work to
more fully characterize its safety profile. When applied
by a professional with appropriate care, DSF is likely
safe. The gingiva and oral mucosa are not inflamed,
ulcerated or pigmented.
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